艾塞利斯制药 EXEL
$69.57 +$0.86 (+1.25%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $69.57 0.00%
开盘$68.35
昨收$68.71
当日区间$68.01 – $70.32
成交量2.00M
市值$16.98B
市盈率（TTM）20.8
股息率–
财报
财报日平均波动±7.4%近16次财报
收涨次数9 / 1656% 的概率
最佳反应+20.8%
最差反应-16.8%
每次财报后次日股价变动
| 季度 | 财报日期 | 时段 | 隐含波动 | 实际波动 | 较隐含波动 |
|---|---|---|---|---|---|
| 2026/Q3 | 29 Oct 2026 | After Market | ±8.3% | +4.82% | 符合区间 |
| 2026/Q2 | 5 Aug 2026 | After Market | ±7.2% | -7.94% | 超出定价预期 |
| 2026/Q1 | 5 May 2026 | After Market | ±6.4% | +9.64% | 超出定价预期 |
| 2025/Q4 | 10 Feb 2026 | After Market | ±6.8% | -0.09% | 符合区间 |
| 2025/Q3 | 4 Nov 2025 | After Market | ±9.5% | +6.52% | 符合区间 |
| 2025/Q2 | 28 Jul 2025 | After Market | ±11.4% | -16.78% | 超出定价预期 |
| 2025/Q1 | 13 May 2025 | After Market | ±6.7% | +20.84% | 超出定价预期 |
| 2024/Q4 | 11 Feb 2025 | After Market | ±7.7% | -0.03% | 符合区间 |
| 2024/Q3 | 29 Oct 2024 | After Market | ±7.6% | +12.91% | 超出定价预期 |
| 2024/Q2 | 6 Aug 2024 | After Market | ±14.9% | +13.09% | 符合区间 |
| 2024/Q1 | 30 Apr 2024 | After Market | ±9.0% | -6.54% | 符合区间 |
| 2023/Q4 | 6 Feb 2024 | After Market | ±6.6% | -7.56% | 超出定价预期 |
| 2023/Q3 | 1 Nov 2023 | After Market | ±7.6% | -4.23% | 符合区间 |
| 2023/Q2 | 1 Aug 2023 | After Market | ±6.2% | +3.62% | 符合区间 |
| 2023/Q1 | 9 May 2023 | After Market | ±8.8% | +0.78% | 符合区间 |
| 2022/Q4 | 7 Feb 2023 | After Market | ±7.6% | +2.72% | 符合区间 |
"隐含波动"指财报发布前期权市场定价的预期波幅。"波动"指财报发布后首个交易日的股价变化。
营收构成
2026/Q2 季度
按业务线
基本面
最新报告季度：Q3, ended Sep 2026
营收$658.70M+10.2% YoY
营业利润$268.42M+4.7% YoY
净利润$218.10M+12.7% YoY
摊薄每股收益$0.85+23.2% YoY
自由现金流$269.89M-4.8% YoY
经营现金流$279.96M
营收，近8个季度
净利润，近8个季度
盈利能力与资产负债表
毛利率96.3%
营业利润率40.2%
净利率35.5%
净资产收益率44.3%
资产收益率33.2%
投入资本回报率38.5%
流动比率3.21
负债/资产比率27.0%
现金及投资$892.02M
总负债$162.20M
净现金（净负债）$729.82M
自由现金流/营收45.8%
暂无评论——快来第一个聊聊 EXEL。
登录后参与讨论。